• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study: Lower IOP, medication burden in OAG patients


MIGS drainage device offers hope for challenging cases.

A novel supraciliary microinvasive glaucoma surgery (MIGS) drainage device (MINIject; iSTAR Medical) lowered IOP by 38% and decreased the number of medications needed by 12 months after implantation, according to Steven Vold, MD, who presented the study data on behalf of the investigators.

The findings were the result of a multicenter, prospective, interventional European trial of the device in patients with uncontrolled open-angle glaucoma (OAG).

Related: The use of MIGS trends and patterns in the US

“This MIGS implant represents a safety advantage of injection of the device into the supraciliary space compared with other surgeries that require a bleb and/or use of an ab-externo approach,” Vold said.

Vold, who is in private practice in Fayetteville, Arkansas, said the 5-mm supraciliary device is made of soft and flexible biocompatible silicone that was successfully implanted in 29 eyes in a standalone, ab-interno procedure. The device adapts to the scleral curvature, and 12 months after implantation remained stable in the implant location with no migration.

The primary study end point was the success rate 6 months postoperatively that exceeded 60%. Vold explained that the study defined success as a diurnal IOP of 21 mm Hg or less but more than 5 mm Hg with more than a 20% reduction in the IOP from baseline.

Related: Home IOP monitoring may be aftereffect of COVID-19 pandemic

Study findings
The patients’ mean baseline diurnal IOP was 24.6 plus or minus 3.8 mm Hg with use of a mean of 2.9 plus or minus 1.2 IOP-lowering medications. Six months after implantation, more than three-fourths of the patients met the primary end point.1

Twelve months after implantation, the mean diurnal IOP had decreased by 9.4 mm Hg, a 38% reduction from baseline, to 15. mm Hg, and the patients used a mean of 1.3 medications; 45% of patients no longer required medication, he reported.

Serious adverse events associated with the device included an IOP increase in 3 patients and eye pain, corneal erosion, and chorioretinal folds in 1 patient each; all of these resolved. The corneal endothelial cell density changed minimally.

Related: Eliminating the potential land mines in glaucoma surgery

“This supraciliary MIGS device implanted in a stand-alone procedure was shown to be a powerful treatment option to reduce IOP by 38% 12 months post implantation while decreasing the need for medication in patients with open-angle glaucoma,” the investigators concluded.

Investigators are still waiting for long-term results, up to 24 months. No date for their completion was given.


Steven Vold, MD

This article was adapted from Vold’s presentation at the American Glaucoma Society’s 2021 virtual annual meeting. Vold is a consultant to iSTAR Medical.



1. García Feijoó J, Denis P, Hirneiß C, et al; STAR-II Investigators. A European study of the performance and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-II). J Glaucoma. 2020;29(10):864-871. doi:10.1097/IJG.0000000000001632

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.